Initiation of metastatic breast carcinoma by targeting of the ductal epithelium with adenovirus-cre: A novel transgenic mouse model of breast cancer

Journal of Visualized Experiments

Volumn , Issue 85, 2014, Pages

  Rutkowski, Melanie R ^a   Allegrezza, Michael J ^a   Svoronos, Nikolaos ^a   Tesone, Amelia J ^a   Stephen, Tom L ^a   Perales Puchalt, Alfredo ^a   Nguyen, Jenny ^a   Zhang, Paul J ^b   Fiering, Steven N ^c   Tchou, Julia ^b,d,e   Conejo Garcia, Jose R ^a  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenovirus Cre; Breast cancer; Intraductal injection; Issue 85; Latent mutations; Medicine; Metastasis; Transgenic mice

Indexed keywords

EID: 84922228853     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/51171     Document Type: Article

References (34)

1. Youlden, D. et al. The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 36, 237-248, doi:10.1016/j.canep.2012.02.007 (2012).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. Cancer J. Clin. 62, 10-29, doi:10.3322/caac.20138 (2012).
3. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98, 10869-10874, doi:10.1073/pnas.191367098 (2001).
4. Gatza, M. et al. A pathway-based classification of human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 107, 6994-6999, doi:10.1073/pnas.0912708107 (2010).
5. Bastien, R. et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med. Genom. 5, 44, doi:10.1186/1755-8794-5-44 (2012).
6. Montagna, E. et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin. Breast Cancer. 13, 31-39, doi:10.1016/j.clbc.2012.09.002 (2013).
7. Karrison, T. G., Ferguson, D. J. & Meier, P. Dormancy of mammary carcinoma after mastectomy. J. Natl. Cancer Inst. 91, 80-85 (1999).
8. Rakha, E. et al. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer. 118, 3670-3680, doi:10.1002/cncr.26711 (2012).
9. Kim, I. & Baek, S. Mouse models for breast cancer metastasis. Biochem. Biophys. Res. Commun. 394, 443-447, doi:10.1016/j.bbrc.2010.03.070 (2010).
10. Vargo-Gogola, T. & Rosen, J. Modelling breast cancer: one size does not fit all. Nat. Rev. Cancer. 7, 659-672, doi:10.1038/nrc2193 (2007).
11. Archer, T. et al. Steroid hormone receptor status defines the MMTV promoter chromatin structure in vivo. J. Steroid Biochem. Mol. Biol. 53, 421-429, doi:10.1016/0960-0760(95)00088-h (1995).
12. Cato, A., Henderson, D. & Ponta, H. The hormone response element of the mouse mammary tumour virus DNA mediates the progestin and androgen induction of transcription in the proviral long terminal repeat region. EMBO J. 6, 363-368 (1987).
13. Schoenenberger, C., Zuk, A., Groner, B., Jones, W. & Andres, A. Induction of the endogenous whey acidic protein (Wap) gene and a Wap-myc hybrid gene in primary murine mammary organoids. Dev. Biol. 139, 327-337, doi:10.1016/0012-1606(90)90302-y (1990).
14. Li, Y. et al. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol. Biol. 2, 2 (2001).
15. Martelli, C. et al. In vivo imaging of lymph node migration of MNP-and (111)In-labeled dendritic cells in a transgenic mouse model of breast cancer (MMTV-Ras). Mol. Imaging Biol. 14, 183-196, doi:10.1007/s11307-011-0496-0 (2012).
16. Klover, P. J. et al. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia. 12, 899-905 (2010).
17. Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2, 451-461, doi:S153561080200212X [pii] (2002).
18. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486, 405-409, doi:10.1038/nature11154 (2012).
19. Miyakis, S., Sourvinos, G. & Spandidos, D. A. Differential expression and mutation of the ras family genes in human breast cancer. Biochem. Biophys. Res. Commun. 251, 609-612, doi:S0006-291X(98)99527-4 [pii]10.1006/bbrc.1998.9527 (1998).
20. Malaney, S. & Daly, R. J. The ras signaling pathway in mammary tumorigenesis and metastasis. J. Mammary Gland Biol. Neoplasia. 6, 101-113 (2001).
21. Loboda, A. et al. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med. Genomics. 3, 26, doi:1755-8794-3-26 [pii] 10.1186/1755-8794-3-26 (2010).
22. von Lintig, F. C. et al. Ras activation in human breast cancer. Breast Cancer Res. Treat. 62, 51-62 (2000).
23. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer. 3, 11-22, doi:10.1038/nrc969 nrc969 [pii] (2003).
24. Eckert, L. B. et al. Involvement of Ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res. 64, 4585-4592, doi:10.1158/0008-5472.CAN-04-039664/13/4585 [pii] (2004).
25. Hollestelle, A., Elstrodt, F., Nagel, J., Kallemeijn, W. & Schutte, M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 5, 195-201, doi:10.1158/1541-7786.mcr-06-0263 (2007).
26. Jackson, E. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248, doi:10.1101/gad.943001 (2001).
27. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425, doi:10.1038/ng747 (2001).
28. Scarlett, U. et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209, 495-506, doi:10.1084/jem.20111413 (2012).
29. Vooijs, M., Jonkers, J. & Berns, A. A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent. EMBO Rep. 2, 292-297, doi:10.1093/embo-reports/kve064 (2001).
30. Young, N., Crowley, D. & Jacks, T. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res. 71, 4040-4047, doi:10.1158/0008-5472.can-10-4563 (2011).
31. Dinulescu, D. et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11, 63-70, doi:10.1038/nm1173 (2005).
32. Landua, J., Visbal, A. & Lewis, M. Methods for preparing fluorescent and neutral red-stained whole mounts of mouse mammary glands. J. Mammary Gland Biol. Neoplasia. 14, 411-415, doi:10.1007/s10911-009-9155-3 (2009).
33. Barham, W., Sherrill, T., Connelly, L., Blackwell, T. S. & Yull, F. E. Intraductal injection of LPS as a mouse model of mastitis: signaling visualized via an NF-kappaB reporter transgenic. J. Vis. Exp. e4030, doi:4030 [pii] 10.3791/4030 (2012).
34. Murata, S. et al. Ductal access for prevention and therapy of mammary tumors. Cancer Res. 66, 638-645, doi:10.1158/0008-5472.can-05-4329 (2006).